Shark Tank’s Kevin O’Leary Deep Dives Into Psychedelics
Shark Tank investor Kevin O’Leary is a big fan of psychedelics. Here’s everything you need to know.
Psychedelic Spotlight News
Lamar Odom Documentary About His Recovery Through Psychedelics Makes Its Debut
Former NBA star Lamar Odom details his recovery from substance abuse with the aid of psychedelic medicine in a new documentary.
MindMed Conference Call Recap & My THOUGHTS (MMED / MNMD)
Hey guys! Here’s the recap of MindMed’s (MMED / MNMD/ MMQ) Q1 conference call. They added lots of color on their different projects, and provided us with a lot of interesting new information. So, in this episode, we will cover a few topics. These are:
1. MindMed’s Mission
2. Their Talent acquisition
3. The Progress of their different clinical trials
4. The future
Timestamps:
0:00 – Intro
1:59 – MindMed’s Mission
4:36 – MMED’s talent acquisition
7:24 – MindMed’s clinical trial progress
10:48 – Psychiatry department : Project Lucy
14:17 – Addiction department : Project Layla (18MC)
18:33 – Pain department: Project Angie to treat pain card
22:56 – Neurology department: Project Flow using LSD microdosing to treat ADHD
23:43 – MindMed (MMED / MNMD) and its future plans
Enjoy!
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
Video editing: @themyaholy
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #PsychedelicStocks #MNMD
PharmaDrug Launches E-Store Positioned for U.S. Psychedelic Sales
PharmaDrug is bringing an online shop to the U.S. for sales of functional mushrooms and psychedelics once legal.
What Is MDMA? Meet the Psychedelic Treatment That Could Make PTSD Obsolete
What is MDMA? This psychedelic is showing promise as a treatment for PTSD and depression.
Interview With David Champion
Maya Health’s Co-Founder and CEO, David Champion, discusses the importance of data and analytics in the growing psychedelic community.
Algernon to Become the First Company in the World to Study DMT for Stroke Patients
Algernon Pharmaceuticals has received FDA approval to study DMT for use in stroke patients to help rebuild synaptic connections.
What Is Psilohuasca? How and Why This Psychedelic Combo Is Going Mainstream
What is psilohuasca? This psychedelic combo marries MAO inhibitors with psilocin for an extended journey into healing.
FDA Green-Lights Ketamine Study for Side Effects of Parkinson’s Disease Treatment
Research into ketamine as a potential treatment for Parkinson’s patients suffering from drug side effects is getting FDA approval.
Could Psychedelics Cure Color Blindness? New Data Sees a Bright Future
Could psychedelics help people suffering from color blindness? New research sees great potential with lsd and psilocybin.
End of content
End of content